These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24636383)

  • 1. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
    Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib for the treatment of multiple myeloma patients.
    Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M
    Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in multiple myeloma.
    Cecchi M; Caccese E; Messori A
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.
    Ishak J; Rodrigues F
    Eur J Haematol; 2011 Jul; 87(1):95; author reply 96-7. PubMed ID: 21692852
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
    Mehta J; Duff SB; Gupta S
    Manag Care Interface; 2004 Sep; 17(9):52-61. PubMed ID: 15521286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
    Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
    Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.